 |
|
 |
|
|
NCCTG N05C7 “Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III Randomized, Double-Blind Placebo Controlled Study”
NCCTG N063D“Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) study: A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer ”
Principal Investigator for the the NSABP FRP FB5 study DR. JOHN SMITH II, PROVIDENCE HEALTH SYSTEM |
|
|
 |
|
 |
|
|
|
|
|
|
|
|
Welcome to the Columbia River Oncology Program!
|
|
|
|
The Columbia River Oncology Program (CROP) is a Community Clinical Oncology Program (CCOP) currently in its 22nd year. The National Cancer Institute (NCI) oversees this program. Consortium affiliates include health care systems and providers in the metropolitan Portland, Oregon and Vancouver, Washington area.
Adventist Medical Center, Legacy Health System, Northwest Cancer Specialists, Providence Health System, and Southwest Washington Medical Center take part in CROP. CROP provides state of the art clinical trials in cancer prevention, symptom control and treatments, advancing the knowledge of cancer and improving the health of our community.
CROP's Research Bases
CROP's Goals
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical Research Studies
|
|
|
|
|
|
|
|
|
|